BLISSGVS
Bliss GVS Pharma Limited (BLISSGVS) Stock Analysis
Bliss GVS Pharma Limited is an Indian pharmaceutical company focused on formulations and APIs. It markets medicines in domestic and international markets through distributors and partners. Therapeutic segments include women's health and general pharma. The company is listed on Indian stock exchanges and operates from India.
Healthcare › Drug Manufacturers - Specialty & Generic
₹660.70
-3.06% 1W | +342.50% 52W
Market Cap
7.0k CR
P/E Ratio
52.4
52W High
₹739.9
52W Low
₹118
Div. Yield
0.22%
Beta
1.2
50 DMA
₹621
200 DMA
₹383.2
Profit Margin
13.5%
Inst. Own.
8.4%
⚠️ BREAKDOWN
⚠️ BREAKDOWN
Fundamentals
Profit & Loss
| Metric | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 160 | 212 | 201 | 198 | 184 | 218 | 210 | 198 | 207 | 244 | 218 | 257 | 286 |
| Expenses | 135 | 158 | 157 | 170 | 149 | 176 | 181 | 177 | 166 | 201 | 183 | 213 | 209 |
| Operating Profit | 24 | 54 | 44 | 28 | 34 | 41 | 30 | 21 | 41 | 43 | 35 | 44 | 76 |
| OPM % | 15% | 26% | 22% | 14% | 19% | 19% | 14% | 11% | 20% | 18% | 16% | 17% | 27% |
| Other Income | 5 | 13 | 5 | -24 | 4 | 5 | 15 | 12 | 35 | 8 | 16 | 11 | 10 |
| Interest | 1 | 1 | 2 | 2 | 2 | 4 | 1 | 2 | 5 | 3 | 1 | 2 | 1 |
| Depreciation | 6 | 6 | 7 | 7 | 7 | 7 | 8 | 8 | 8 | 8 | 8 | 9 | 10 |
| Profit before tax | 22 | 59 | 40 | -4 | 30 | 36 | 36 | 23 | 63 | 41 | 41 | 45 | 75 |
| Tax % | 34% | 27% | 27% | 24% | 26% | 28% | 29% | 29% | 30% | 30% | 39% | 18% | 32% |
| Net Profit | 14 | 43 | 29 | -5 | 22 | 26 | 26 | 17 | 44 | 29 | 25 | 37 | 51 |
| EPS in Rs | 1.41 | 4.05 | 2.64 | -0.87 | 1.97 | 2.31 | 2.26 | 1.47 | 4.08 | 2.58 | 2.20 | 3.36 | 4.72 |
| Metric | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 407 | 547 | 798 | 815 | 899 | 689 | 577 | 747 | 752 | 770 | 810 | 927 | 1,005 |
| Expenses | 304 | 391 | 596 | 618 | 739 | 566 | 471 | 629 | 634 | 620 | 683 | 760 | 806 |
| Operating Profit | 103 | 156 | 203 | 197 | 160 | 123 | 107 | 118 | 117 | 151 | 127 | 168 | 199 |
| OPM % | 25% | 29% | 25% | 24% | 18% | 18% | 18% | 16% | 16% | 20% | 16% | 18% | 20% |
| Other Income | 20 | 24 | 12 | -8 | 35 | 26 | 20 | -42 | 18 | -0 | 36 | 67 | 45 |
| Interest | 16 | 19 | 20 | 23 | 4 | 8 | 6 | 5 | 10 | 7 | 8 | 12 | 7 |
| Depreciation | 11 | 13 | 20 | 21 | 9 | 13 | 17 | 17 | 19 | 26 | 29 | 33 | 35 |
| Profit before tax | 96 | 148 | 175 | 145 | 182 | 129 | 104 | 54 | 106 | 117 | 126 | 190 | 202 |
| Tax % | 36% | 32% | 36% | 39% | 30% | 26% | 29% | 57% | 28% | 30% | 28% | 29% | |
| Net Profit | 61 | 100 | 113 | 89 | 127 | 95 | 74 | 23 | 77 | 82 | 90 | 135 | 142 |
| EPS in Rs | 5.81 | 8.00 | 7.95 | 5.70 | 11.99 | 9.43 | 6.64 | 1.45 | 6.80 | 7.21 | 8.00 | 12.21 | 12.86 |
| Dividend Payout % | 12% | 6% | 8% | 18% | 8% | 5% | 8% | 34% | 7% | 7% | 6% | 4% |
Growth — CAGR
| Metric | 3Y | 5Y | 10Y |
|---|---|---|---|
| Revenue CAGR | 7.0% | 10.0% | 5.0% |
| Profit CAGR | 23.0% | 14.0% | 5.0% |
Shareholding Pattern
Promoters35.44%
FIIs12.65%
DIIs6.54%
Public45.37%
Promoters35.39%
FIIs13.27%
DIIs5.98%
Public45.36%
Promoters35.36%
FIIs14.54%
DIIs5.78%
Public44.32%
Promoters35.36%
FIIs10.45%
DIIs5.04%
Public49.15%
Promoters35.01%
FIIs8.07%
DIIs9.46%
Public47.45%
Promoters35.04%
FIIs16.60%
DIIs6.63%
Public41.73%
Promoters34.97%
FIIs14.74%
DIIs6.59%
Public43.71%
Promoters35.29%
FIIs13.18%
DIIs6.55%
Public44.98%
Promoters35.36%
FIIs10.45%
DIIs5.04%
Public49.15%
Promoters35.01%
FIIs8.07%
DIIs9.46%
Public47.45%
BLISSGVS
Holdings Analysis
Key strengths & risk signals
73
Overall
63
Fundamental
83
Technical
Risks (2)
TOO MUCH PUBLIC HOLDING! 41.73% public ownership - higher volatility risk.
WEAK MOMENTUM! Limited price growth - -3.1% (1 week), -8.4% (1 month), 30.8% (3 months).
Strengths (4)
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
BULLISH TREND! 50-day average (621.0) is above 200-day average (383.2) - positive signal.
EXCELLENT YEAR! Stock gained 342.5% in the last year.
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 458,696 vs down days: 219,354. Ratio: 2.09x
Fundamental & Technical Analysis
73Overall
63Fundamental
83Technical
Fundamental Breakdown
Growth Quality
23/30
Revenue CAGR: 7.2% (MODERATE, 8/15). Profit CAGR: 22.1% (EXCELLENT, 15/15).
Profit Margin
5/10
DECENT EFFICIENCY! 13.5% profit margin - acceptable profitability.
PEG Valuation
7/10
OVERVALUED! PEG of 2.37 means expensive relative to growth rate.
Dividend Yield
3/10
NEGLIGIBLE DIVIDEND! 0.22% yield - little to no income.
Debt to Equity
10/10
VERY LOW DEBT! D/E of 0.00 - excellent financial health.
Public Holding
5/20
TOO MUCH PUBLIC HOLDING! 41.73% public ownership - higher volatility risk.
Stability Index
10/10
PERFECT RECORD! Revenue has grown consistently every year. Exceptional business stability.
Technical Breakdown
Moving Averages
12/10
BULLISH TREND! 50-day average (621.0) is above 200-day average (383.2) - positive signal.
Price Position
8/10
STRONG POSITION! Current price (660.7) is above both moving averages.
Trend Pattern
10/20
BREAKDOWN! Stock has broken below support levels - weakness present.
52W Performance
10/10
EXCELLENT YEAR! Stock gained 342.5% in the last year.
Volume Sentiment
30/30
BULLISH SENTIMENT! In last 30 days: 16 up days, 14 down days. Avg volume on up days: 458,696 vs down days: 219,354. Ratio: 2.09x
RSI
3/5
NEUTRAL! RSI at 49.5 - balanced momentum.
52W Range
5/5
STRONG! Trading at 87.3% of 52W range - near yearly highs.
Momentum
2/5
WEAK MOMENTUM! Limited price growth - -3.1% (1 week), -8.4% (1 month), 30.8% (3 months).
Beta
3/5
ABOVE MARKET! Beta of 1.20 - more volatile than market.
Peer Comparison
Healthcare · Drug Manufacturers - Specialty & Generic · 8 stocks
| Stock | Price | P/E | Profit Margin | Revenue CAGR 5Y | Profit CAGR 5Y | 52W Change | Stock Strength | Trendline | YoY Profit | QoQ Profit | YoY Revenue | QoQ Revenue |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BLISSGVS | ₹660.70 | 52.4 | 13.5% | 7.2% | 22.1% | +342.5% | 73 | BREAKDOWN | +16.5% | +40.7% | +37.6% | +11.1% |
| MOREPENLAB | ₹128.30 | 50.1 | 7.2% | 8.4% | 34.9% | +154.1% | 73 | BREAKDOWN | +427.1% | +259.2% | +34.1% | +17.6% |
| SPARC | ₹191.80 | 3.9 | 83.0% | -45.3% | – | +40.8% | 60 | CONSOLIDATING DOWN | -59.9% | -101.2% | +315.6% | -97.8% |
| AARTIPHARM | ₹867.60 | 36.9 | 10.4% | -2.6% | -3.3% | +7.1% | 54 | APPROACHING RESISTANCE | +65.4% | +24.5% | +38.7% | -8.0% |
| IOLCP | ₹203.70 | 35.6 | 6.7% | 1.6% | -0.4% | +99.9% | 58 | BREAKDOWN | +90.0% | +21.1% | +37.1% | +22.1% |
| INNOVACAP | ₹1,053.40 | 39.1 | 8.8% | 20.1% | 27.5% | +30.4% | 73 | BREAKDOWN | +42.3% | +15.7% | +34.0% | +5.2% |
| SUVEN | ₹285.40 | – | – | -19.3% | – | +44.2% | 52 | BREAKDOWN | +147.8% | +179.8% | +89.5% | +140.0% |
| FDC | ₹348.60 | 19.4 | 13.4% | 6.8% | 13.2% | -21.8% | 72 | BREAKOUT | +9.1% | +28.1% | +3.0% | +14.2% |
Data from TradeAlone · Updated daily
No news tagged for BLISSGVS yet.
